NP and PA

John Browning, MD, FAAD, FAAP, MBA, discusses the impact of the recent FDA approval of secukinumab (Cosentyx, Novartis) for the treatment of moderate to severe plaque psoriasis in children and adolescents.

Sunscreen is a necessary preventive tool. However, there are concerns about UV agent absorption, environmental impact, and possible correlations with frontal fibrosing alopecia (FFA). Here is a look at whether those worries are justified by research.

Recent therapeutic advances in topical and systemic therapy offer new options for cases that have not responded to established treatment approaches.

Diagnosis, risk assessment and treatment of congenital melanocytic nevi (CMN), as well as melanoma, require specific strategies for pediatric patients.

One expert says the action of demodex folliculorum and the composition of the symbiotic microbiota in the skin of patients with rosacea may provide valuable insights into the pathogenesis and pathophysiology of this widespread skin disease.

A recent study finds that payer sway in a region hurts not only patient care, but also physician pay.

Next-generation therapies explore solutions other than laser treatments, and are less invasive, safer and require less downtime.

Half of patients are satisfied with their atopic dermatitis treatment and more than half of patients worry about topical steroid side effects, addiction and withdrawal, according to a recent study.

The National Psoriasis Foundation’s (NPF) COVID-19 Task Force has recently published 22 guidance statements related to managing psoriatic disease during the pandemic in the Journal of American Academy of Dermatology (JAAD).

In recently presented data at the 29th annual European Academy of Dermatology and Venereology (EADV) virtual congress, baricitinib demonstrated significant long-term safety and efficacy in treating moderate-to-severe atopic dermatitis.

Only half of patients are satisfied with their atopic dermatitis treatment; yet, only about one-third discuss their quality-of-life concerns with their healthcare provider, a recent survey reveals.

Steven R. Feldman, M.D., Ph.D., describes several tactics based on concepts from behavioral economics that can be implemented in counseling conversations with patients.

ICYMI, this week’s edition features a video series on social media use in dermatology, the launch of our new podcast, as well as articles about FDA approvals for acne and cSCC, progress in epidermolysis bullosa, new rosacea management treatment, plus more.

Efforts are underway to identify new therapeutic methods that can offer improved outcomes for patients with hidradenitis suppurativa.

In light of the ongoing pandemic, Vivian Shi, M.D., discusses potential risks dermatologists will want to keep in mind when evaluating patients currently taking immunomodulator or immunosuppressant drugs.

Dr. Suneel Chilukuri of Refresh Dermatology located in Houston, Tx., sits down with Dermatology Times to discuss the aesthetic needs of millennial patients and what they've been requesting, such as treatment for 'tech neck' and much more.

A recent clinical review proves trifarotene 0.005% cream is an effective and safe treatment for acne vulgaris on the face and neck in patients 9 years and older. Currently, the drug is one of four topical retinoid acne treatments available on the market.

The interleukin-23 antagonist guselkumab demonstrated greater efficacy compared with adalimumab and secukinumab at week 48 in controlled clinical trials investigating treatment of moderate-to-severe plaque psoriasis.

Mast cells appear to play an intricate role in the pathophysiology of rosacea and could serve as potential targets for future therapies, according to recent study findings.

This week, we spoke with Mark Lebwohl, M.D., about his recent article featured in the Journal of the American Academy of Dermatology regarding biologic use in dermatology patients during the COVID-19 pandemic.

Recent evidence of increased mast cell activity suggests mast cell stabilization as a target for rosacea treatment.

REVIAN, Inc. releases positive data from their study investigating the REVIAN RED dual wavelength 620 nm and 660 nm light therapy device as a therapy for scalp pruritus and irritation.

Speaking about device-based acne treatments at Maui Derm for Dermatologists 2020 meeting, Fernanda Sakamoto, Ph.D., M.D., discussed PDT and other approaches for targeting the sebaceous gland.

Hilary E. Baldwin, M.D. discusses advances in acne treatment that have expanded treatment options, allowing physicians to improve outcomes in patients with moderate-to-severe acne.

Eli Lilly announces the U.S. Food and Drug Administration approval of ixekizumab (Taltz) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6 and under 18 who are also eligible for phototherapy and systemic therapy.

HEINE, a global primary diagnostic instrument manufacturer, announces two new dermatoscopes available for purchase in the U.S.

Read more on the variety of new treatment options for acne, with even more awaiting approval.

Read insights from James Q. Del Rosso, D.O., as he discusses antibiotic resistance, isotretinoin relapse, and laboratory monitoring for patients on isotretinoin and spironolactone.

It is important for clinicians to stay abreast with the latest data coming out of trials and individually consult their hair loss patients accordingly on a case by case basis, says this expert.